Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 277

Sort by

Sort Order Select

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Kenta Mukaihara, MD PhD, Mattia D'Agostino, MD, Cristina Panaroni, PhD, Keertik Fulzele, PhD, Tomoaki Mori, MD PhD, Ka Tat Siu, PhD, Shrikanta Chattopadhyay, MBBS, Noopur Raje, MD

Blood (2019) 134 (Supplement_1): 4382.

https://doi.org/10.1182/blood-2019-130462

Published: 2019

Journal Articles

Managing Multiple Myeloma with Second and Later Lines of Therapy: A Challenge in Developing Countries

Venkateswar Rao Pydi, MBBS, MD, Stalin Chowdary Bala, MBBS, MD DM, DNB, Sadashivudu Gundeti, DM, MBBS, MD

Blood (2019) 134 (Supplement_1): 5564.

https://doi.org/10.1182/blood-2019-127943

Published: 2019

Journal Articles

[ 18 f]-( 2S , 4R )-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma

Nicola Giuliani, Silvia Valtorta, PhD, Martina Chiu, PhD, Denise Toscani, PhD, Andrea Sartori, PhD, Angela Coliva, PhD, Arianna Brevi, Stefania Battaglia, MS, Emanuela Vicario, PhD, Giuseppe Taurino, MS, Matteo Grioni, Francesca Ferlenghi, PhD, Livia Ruffini, MD, Federica Vacondio, PhD, Franca Zanardi, PhD, Matteo Bellone, MD, Rosa Maria Moresco, PhD, Ovidio Bussolati, MD PhD

Blood (2019) 134 (Supplement_1): 5542.

https://doi.org/10.1182/blood-2019-127935

Published: 2019

Journal Articles

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

Loula Papageorgiou, Patrick Van Dreden, PhD, Meletios A. Dimopoulos, MD, Annette Larsen, Mohamad Mohty, MD PhD, Ismail Elalamy, MD PhD, Grigorios T. Gerotziafas

Blood (2019) 134 (Supplement_1): 2425.

https://doi.org/10.1182/blood-2019-124650

Published: 2019

Journal Articles

Real Life Use of Imaging in the Management of Newly Diagnosed Patients with Myeloma- Practical Perspectives from a UK Hospital

Ke Xu, MD, Lucy Fowkes, Fenella Willis, Yasmin Reyal

Blood (2019) 134 (Supplement_1): 5513.

https://doi.org/10.1182/blood-2019-121504

Published: 2019

Journal Articles

A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre

Saurabh Mishra, MD DNB, Ashok K Vaid, MDDM, Nitin Sood, MDFRCPath,MRCP, Manorama Bhargava, Bhuvan Chugh, DNB, Roshan Dixit, MD, Amrita Ramaswami, MDDM, Devender Sharma, MD

Blood (2019) 134 (Supplement_1): 5559.

https://doi.org/10.1182/blood-2019-125752

Published: 2019

Journal Articles

Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma

Smith Giri, MBBS, Ellice Y. Wong, MD, Michal Rose, MD, Roxanne Wadia, MD, Lesley S. Park, PhD MPH, Amy C. Justice, MD PhD, Natalia Neparidze, MD

Blood (2018) 132 (Supplement 1): 3162.

https://doi.org/10.1182/blood-2018-99-115633

Published: 2018

Journal Articles

Prognosis after Upfront Radiation Therapy in Plasma Cell Myeloma: Analysis of the National Cancer Data Base

Xavier Orcutt, BA, Peter Barth, MD, Adam J Olszewski, MD

Blood (2018) 132 (Supplement 1): 3230.

https://doi.org/10.1182/blood-2018-99-110108

Published: 2018

Journal Articles

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Blood (2018) 132 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2018-99-114106

Published: 2018

Journal Articles

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Chang-Ki Min, MD PhD, Sung-Soo Yoon, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Shang-Yi Huang, MD, PhD, Cheng-Shyong Chang, MD, Raymond Siu Ming Wong, Kazuyuki Shimizu, MD PhD, Nan Gao, Anthony Glennane, MD, Xuesong Guan

Blood (2018) 132 (Supplement 1): 3251.

https://doi.org/10.1182/blood-2018-99-113132

Published: 2018

Journal Articles

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Evangelos Terpos, MD PhD, Wolfgang Willenbacher, MD, Kazuyuki Shimizu, MD PhD, Ramon García-Sanz, MD PhD, Anthony Glennane, MD, Xuesong Guan, Daniela Niepel, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2018-99-113587

Published: 2018

Journal Articles

Diagnostic Relevance of 18F-FDG PET/CT in Newly Diagnosed Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) : Single- Center Experience

Viera Sandecka, MD PhD, Ludek Pour, MD, Zdenek Adam, Prof, MD CSc, Martin Stork, MD, Marta Krejci, Prof, MD PhD, Jana Michalcova, MD, Zdenek Kral, MD CSc, Sabina Sevcikova, PhD, Zdeněk Řehák, MD PhD, Renata Koukalova, MD

Blood (2018) 132 (Supplement 1): 1913.

https://doi.org/10.1182/blood-2018-99-111094

Published: 2018

Journal Articles

FDG and FCH PET/CT of Multiple Myeloma at Various Clinical Situations: Lesion Detection, Proposal for a Patient-Based "Summ" Score and Reproducibility of Scoring

Jules Zhang-Yin, MD, Sona Balogova, Mor Seny Gueye, Mohamad Mohty, MD PhD, Françoise Montravers, Jean Noel Talbot, Laurent Garderet

Blood (2018) 132 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2018-99-114024

Published: 2018

Journal Articles

Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer

Shehab Mohamed, MD, Mohamed A Yassin, MBBS, MSc, Abdulqadir Jeprel Nashwan, BSN, MSN, RN, CBT-HMS, Halima El Omri, Firyal Ibrahim, MB, CHB, PhD, Susana El akiki, PhD

Blood (2018) 132 (Supplement 1): 5140.

https://doi.org/10.1182/blood-2018-99-116084

Published: 2018

Journal Articles

The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study

Sigrun Thorsteinsdottir, MD, Ingigerdur S Sverrisdottir, MD, Gauti Gislason, MSc, Ola Landgren, MD PhD, Ingemar Turesson, MD PhD, Magnus Björkholm, MD PhD, Sigurdur Y Kristinsson, MD PhD

Blood (2018) 132 (Supplement 1): 4490.

https://doi.org/10.1182/blood-2018-99-115403

Published: 2018

Journal Articles

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Attaya Suvannasankha, MD, Colin Crean, BS, Isaac Carrera Ochoa, G David Roodman, MD PhD, John Chirgwin, PhD

Blood (2018) 132 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2018-99-115680

Published: 2018

Journal Articles

Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study

Tamir Shragai, MD, Moshe E. Gatt, MD, Adir Shaulov, MD, Eirini Katodritou, MD, Theodora Triantafyllou, MD, Noa Lavi, MD, Anastasia Pouli, MD PhD, Anastasia Sioni, Iuliana Vaxman, MD BA, Miri Zektser, MD, Chezi Ganzel, MD, Noam Benyamini, MD, Svetlana Trestman, MD, Tomer ziv Baran, PhD, Yael C Cohen, MD, Irit Avivi, MD

Blood (2018) 132 (Supplement 1): 5578.

https://doi.org/10.1182/blood-2018-99-116372

Published: 2018

Journal Articles

Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure

Simone A Minnie, David Smith, Kate H Gartlan, PhD, Thomas S Watkins, Kate A Markey, PhD MBBS, Camille Guillerey, PhD, Rachel D Kuns, BSc, Kelly R Locke, Antiopi Varelias, PhD, Ping Zhang, Nicholas Huntington, PhD, Marta Chesi, PhD, John J Miles, PhD, Mark J Smyth, PhD, Slavica Vuckovic, PhD, Geoffrey R Hill, MD PhD

Blood (2018) 132 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2018-99-118058

Published: 2018

NARROW

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma

Managing Multiple Myeloma with Second and Later Lines of Therapy: A Challenge in Developing Countries

[ 18 f]-( 2S , 4R )-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma

Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study

Real Life Use of Imaging in the Management of Newly Diagnosed Patients with Myeloma- Practical Perspectives from a UK Hospital

A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre

Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma

Prognosis after Upfront Radiation Therapy in Plasma Cell Myeloma: Analysis of the National Cancer Data Base

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study

Diagnostic Relevance of 18F-FDG PET/CT in Newly Diagnosed Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) : Single- Center Experience

FDG and FCH PET/CT of Multiple Myeloma at Various Clinical Situations: Lesion Detection, Proposal for a Patient-Based "Summ" Score and Reproducibility of Scoring

Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer

The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study

Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only